Compositions and methods for reduction of amyloid-beta load
AssigneeModgene, LLC
InventorsJ. Gregor Sutcliffe, Brian S. Hilbush
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of AP levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a compound that results in the modulation of γ-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain AP disorder, such as Alzheimer's disease.
Claims21
A method of treating a subject having a brain Aβ disorder or predisposition to a brain Aβ disorder, comprising peripherally administering a compound that modulates production of Aβ in a peripheral tissue, wherein said compound is an imatinib derivative displaying reduced protein kinase inhibition compared to imatinib.
A method, comprising:
- a) assessing a subject for the presence of a brain Aβ disorder or predisposition to a brain Aβ disorder;
- b) peripherally administering a compound that modulates production of Aβ, wherein said compound does not substantially penetrate the blood brain barrier, wherein said compound comprises imatinib para-diaminomethylbenzene and/or N-desmethyl imatinib;
- and;
- c) after said administering of step b), assessing said subject for a brain Aβ disorder or progression of a brain Aβ disorder.
15-16. (canceled)
A composition comprising:
- i) imatinib para-diaminomethylbenzene or pharmaceutically acceptable salt thereof, and/or N-desmethyl imatinib or pharmaceutically acceptable salt thereof;
- ii) a known therapeutic agent for treating, ameliorating, or reducing risk or severity of a brain Aβ-related disorder, wherein said known therapeutic agent is selected from the group consisting of imatinib, cannabinoids, dimebom, prednisone, ibuprofen, naproxyn, indomethacin;
- statins, selective estrogen receptor molecules, antihypertensives, alpha-blockers, beta-blockers, alpha-beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, diuretics, NSAIDS, and antioxidants;
- and
- iii a pharmaceutically acceptable excipient.
21-23. (canceled)
Dependencies are inferred from the claim text.